Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 187

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma

Open access
Kubiczkova, Lenka, Pour, Ludek, Sedlarikova, Lenka, Hajek, Roman, Sevcikova, Sabina·2014·Journal of Cellular and Molecular Medicine

Abstract

Inhibition of proteasome, a proteolytic complex responsible for the degradation of ubiquitinated proteins, has emerged as a powerful strategy for treatment of multiple myeloma (MM), a plasma cell malignancy. First‐in‐class agent, bortezomib, has demonstrated great positive therapeutic efficacy in MM, both in pre‐clinical and in clinical studies. However, despite its high efficiency, a large proportion of patients do not achieve sufficient clinical response. Therefore, the development of a second‐generation of proteasome inhibitors (PI s) with improved pharmacological properties was needed. Recently, several of these new agents have been introduced into clinics including carfilzomib, marizomib and ixazomib. Further, new orally administered second‐generation PI oprozomib is being investigated. This review provides an overview of main mechanisms of action of PI s in MM, focusing on the ongoing development and progress of novel anti‐proteasome therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jcmm.12279

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 187

Metadata

Authors
Kubiczkova, L., Pour, L., Sedlarikova, L., Hajek, R., & Sevcikova, S.
Venue
Journal of Cellular and Molecular Medicine
Publisher
Wiley
Published
2014-04-08
Volume
18
Issue
6
Pages
947-961
ISSN
  • 1582-1838 (ISSN-L)
  • 1582-4934
OpenAlex
W2052840623
Cited by
187
References
4
FWCI
7.76
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma. https://app.cochat.ai/papers/10.1111/jcmm.12279
The paper
Kubiczkova, L., Pour, L., Sedlarikova, L., Hajek, R., & Sevcikova, S. (2014). Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.12279

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.